Orchestra BioMed Holdings, Inc. (OBIO): who owns it and who trades it
As of Nov 16, 2026, OBIO insiders reported 7 open-market sales worth $439K and 12 purchases worth $6.4M in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Darren Sherman (Director), with $439K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Orchestra BioMed Holdings
From the latest filingsOverall: about as much buying as selling. Famous investors mostly sold. Funds and insiders mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns OBIO
77 funds and institutions reported OBIO shares worth $121M at the end of Q2 2026, about 48% of the company. The largest holder is Rtw Investments, LP with 16.3%.
Funds and institutions (13F) 48%Everyone else 52%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Rtw Investments, LP | 9.56M | 16.33% | $41.2M | +15% |
| Perceptive Advisors LLC | 5.04M | 8.61% | $21.7M | No change |
| BlackRock, Inc. | 2.51M | 4.29% | $10.8M | +295% |
| Vanguard Capital Management LLC | 2.02M | 3.46% | $8.7M | -8% |
| Geode Capital Management, LLC | 1.01M | 1.72% | $4.4M | +108% |
| Alyeska Investment Group, L.P. | 1.00M | 1.71% | $4.3M | No change |
| Propel Bio Management, LLC | 896,701 | 1.53% | $3.9M | No change |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 642,154 | 1.10% | $2.8M | New |
| State Street Corp | 516,050 | 0.88% | $2.2M | +205% |
| Rice Hall James & Associates, LLC | 424,000 | 0.72% | $1.8M | +2131% |
| Charles Schwab Investment Management Inc | 349,544 | 0.60% | $1.5M | +32% |
| Sixth Street Partners Management Company, L.P. | 349,544 | 0.60% | $1.5M | New |
| Northern Trust Corp | 343,640 | 0.59% | $1.5M | +191% |
| UBS Group AG | 325,773 | 0.56% | $1.4M | +548% |
| Vanguard Fiduciary Trust Co | 292,253 | 0.50% | $1.3M | +24% |
| Vanguard Portfolio Management LLC | 274,973 | 0.47% | $1.2M | New |
| Knott David M Jr | 253,651 | 0.43% | $1.1M | No change |
| Flat Footed LLC | 251,372 | 0.43% | $1.1M | New |
| Simplify Asset Management Inc. | 219,387 | 0.37% | $947K | No change |
| Goldman Sachs Group Inc | 179,606 | 0.31% | $775K | +16% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, OBIO insiders reported $6.4M of open-market purchases and $439K of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 9, 2026 | Rtw Investments, Lp +1 | 10% owner | Purchase | 1.20M | $5.00 | $6M | Form 4 |
| Nov 9, 2026 | Eric S Fain | Director | Purchase | 20,000 | $5.00 | $100K | Form 4 |
| Nov 9, 2026 | David P Hochman | Director | Purchase | 5,000 | $5.00 | $25K | Form 4 |
| Nov 9, 2026 | Andrew Lawrence Taylor | CFO | Purchase | 1,000 | $5.00 | $5K | Form 4 |
| Nov 2, 2026 | Darren Sherman | Director | Sale plan | 15,000 | $5.74 | $86.1K | Form 4 |
| Oct 1, 2026 | Darren Sherman | Director | Sale plan | 15,000 | $6.36 | $95.4K | Form 4 |
| Sep 3, 2026 | David P Hochman | Director | Purchase | 10,000 | $4.79 | $47.9K | Form 4 |
| Sep 1, 2026 | Darren Sherman | Director | Sale plan | 15,000 | $4.94 | $74.1K | Form 4 |
| Aug 26, 2026 | Darren Sherman | Director | Purchase | 2,000 | $5.33 | $10.7K | Form 4 |
| Aug 3, 2026 | Darren Sherman | Director | Sale plan | 15,000 | $4.09 | $61.4K | Form 4 |
| Jul 1, 2026 | Darren Sherman | Director | Sale plan | 15,000 | $4.27 | $64K | Form 4 |
| Jun 1, 2026 | David P Hochman | Director | Purchase | 5,000 | $3.83 | $19.1K | Form 4 |
| Jun 1, 2026 | Darren Sherman | Director | Sale plan | 15,000 | $3.87 | $58K | Form 4 |
| May 18, 2026 | Jason Aryeh | Director | Purchase | 665 | $3.75 | $2.5K | Form 4 |
| May 15, 2026 | Jason Aryeh | Director | Purchase | 8,971 | $3.90 | $35K | Form 4 |
| May 15, 2026 | David P Hochman | Director | Purchase | 5,000 | $3.77 | $18.9K | Form 4 |
| May 14, 2026 | Eric S Fain | Director | Purchase | 20,000 | $4.13 | $82.6K | Form 4 |
| Apr 27, 2026 | Rtw Investments, Lp +1 | 10% owner | Sale | 32 | $4.13 | $132 | Form 4 |
| Mar 13, 2026 | David P Hochman | Director | Purchase | 10,000 | $4.29 | $42.9K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Rtw Investments, Lp | 10% owner | $6M | $132 | Nov 9, 2026 |
| Darren Sherman | See Remarks, Director | $10.7K | $439K | Nov 2, 2026 |
| Eric S Fain | Director | $183K | – | Nov 9, 2026 |
| David P Hochman | See Remarks, Director | $154K | – | Nov 9, 2026 |
| Jason Aryeh | Director | $37.5K | – | May 18, 2026 |
| Andrew Lawrence Taylor | Chief Financial Officer | $5K | – | Nov 9, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
OBIO short interest
Low short interest. 4.5% of OBIO shares are sold short: about 1 share in 22. Over the last 12 reports the number of shares short went up 224%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 2.73M OBIO shares were sold short, 4.5% of the shares outstanding, up 7.0% from the report before. At the average daily volume of 390,641 shares, buying them all back would take about 7.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 2.73M | 4.55% | +7% | 390,641 | 7.0 |
| Oct 15, 2026 | 2.55M | 4.25% | +0% | 263,110 | 9.7 |
| Sep 30, 2026 | 2.55M | 4.24% | +7% | 364,835 | 7.0 |
| Sep 15, 2026 | 2.37M | 3.95% | -4% | 360,954 | 6.6 |
| Aug 31, 2026 | 2.46M | 4.09% | +3% | 422,681 | 5.8 |
| Aug 14, 2026 | 2.38M | 3.97% | -2% | 181,707 | 13.1 |
| Jul 31, 2026 | 2.43M | 4.14% | -6% | 181,418 | 13.4 |
| Jul 15, 2026 | 2.59M | 4.42% | +16% | 238,346 | 10.9 |
| Jun 30, 2026 | 2.22M | 3.80% | +79% | 821,124 | 2.7 |
| Jun 15, 2026 | 1.24M | 2.12% | +31% | 220,226 | 5.6 |
| May 29, 2026 | 948,245 | 1.62% | +13% | 251,730 | 3.8 |
| May 15, 2026 | 842,294 | 1.44% | -13% | 262,079 | 3.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Orchestra BioMed Holdings company events
Orchestra BioMed Holdings filed 6 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026AgreementOrchestra BioMed Holdings, Inc. entered into an underwriting agreement with Piper Sandler & Co. and TD Securities (USA) LLC as the representatives of the several underwriters named therein, relating to an underwritten public offering of an aggregate of 15,000,000 shares of the Company’s common… Filing
- Oct 1, 2026AnnouncementThe Company announced that, as of September 30, 2026, 330 patients had been randomized in the BACKBEAT Global Pivotal Trial, exceeding its previously announced target of 316 randomized patients. Filing
- Sep 8, 2026AnnouncementShared information with investors. Filing
- Jun 23, 2026VoteReported shareholder vote results. Filing
- Feb 13, 2026LeadershipThe Board of Directors of Orchestra BioMed Holdings, Inc., upon the recommendation of the Compensation Committee of the Board, approved the 2026 cash bonus plan for all executive officers, which: · establishes annual goals with mid-year key deliverables approved by the Committee or the Board; ·… Filing
- Jan 12, 2026AnnouncementOrchestra BioMed Holdings, Inc. issued a press release titled “Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics,” which press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Orchestra BioMed Holdings financials
Famous investors that hold OBIO
2 of the 50 well-known investors we track reported holding OBIO in their latest 13F filing. The largest position is Ken Griffin's, worth $150K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 24,152 | $150K | 0.0% | -57% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 11,500 | $71.5K | 0.0% | -87% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named OBIO in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Perceptive Advisors LLC | 13G/A | 8.2% |
| Nov 16, 2026 | Perceptive Advisors LLC | 13G/A | 8.2% |
| Nov 12, 2026 | RTW Investments, LP | 13D/A | 16.2% |
| Nov 12, 2026 | RTW Investments, LP | 13D/A | 16.2% |
Questions about Orchestra BioMed Holdings, Inc. (OBIO) stock
Who owns the most OBIO stock?
The largest reported owner of Orchestra BioMed Holdings, Inc. (OBIO) is Rtw Investments, LP, with 16.3% of the company. In total, 77 funds and institutions reported holding OBIO at the end of Q2 2026, together about 48% of the shares. See the largest owners.
Are OBIO insiders buying or selling?
In the last 12 months, OBIO insiders reported 12 open-market purchases worth $6.4M and 7 sales worth $439K. The latest trade was on Nov 9, 2026. See every trade.
What is the short interest in OBIO?
As of Oct 30, 2026, 2.73M OBIO shares were sold short, 4.5% of the shares outstanding, up 7.0% from the report before. At the average daily volume of 390,641 shares, buying them all back would take about 7.0 trading days (days to cover). See the history.
Which famous investors hold OBIO?
2 of the 50 well-known investors we track reported OBIO in their latest 13F filing, including Ken Griffin, Jim Simons. The largest position is worth $150K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.